Novavax (NVAX) Net Margin (2010 - 2026)

Novavax's Net Margin history runs 17 years deep, the most recent figure standing at 6.8% for Q1 2026.

• On a quarterly basis, Net Margin fell 8460.0% year-over-year to 6.8% in Q1 2026; TTM through Mar 2026 was 16.51%, a 5465.0% decrease from a year earlier, with the FY2025 full-year figure at 39.19%, up 6668.0% from the prior year.
• Net Margin declined to 6.8% in Q1 2026 per NVAX's latest filing, from 11.91% in the prior quarter.
• Across five years, Net Margin topped out at 77.8% in Q1 2025 and bottomed at 363.07% in Q1 2023.
• The 5-year median for Net Margin is 50.99% (2022), against an average of 76.3%.
• Across the five-year window, Net Margin soared 32987 bps in 2022 and plunged 39196 bps in 2023, its largest moves.
• Year by year, Net Margin stood at 50.99% in 2022, then retreated by 20 bps to 61.23% in 2023, then sank by 50 bps to 91.76% in 2024, then soared by 113 bps to 11.91% in 2025, then plunged by 157 bps to 6.8% in 2026.
• Per Business Quant, the three latest NVAX Net Margin figures stand at 6.8% (Q1 2026), 11.91% (Q4 2025), and 287.29% (Q3 2025).